Albuterol HFA MDI

DRUG3 trials

Sponsors

Boehringer Ingelheim, Concentrx Pharmaceuticals, Inc.

Conditions

Asthma

Phase 1

Safety and Pharmacokinetics of Halix(TM) Albuterol Unit Dose Disposable Inhaler Versus Albuterol MDI

CompletedNCT03373409

Concentrx Pharmaceuticals, Inc.Asthma

Start: 2017-11-30End: 2018-07-25Updated: 2019-01-30

Phase 2

Combivent® CFC Metered Dose Inhaler (MDI) in Moderate to Severe Asthma

CompletedNCT00096616

Boehringer IngelheimAsthma

Start: 2004-11-30Updated: 2013-11-01

4 Week 2 Way Crossover Double Blind Treatment Phase With Combivent CFC Versus Albuterol Followed by a 4 Week Open Label Combivent Respimat When All Drugs Are Used for Symptom Relief as Needed in Pts With Moderate to Severe Asthma

CompletedNCT00818454

Boehringer IngelheimAsthma

Start: 2008-12-31Updated: 2014-02-14

Related Papers

Efficacy and safety of ipratropium bromide/albuterol compared with albuterol in patients with moderate-to-severe asthma: a randomized controlled trial

UNC Libraries2020-04-15

Efficacy and safety of ipratropium bromide/albuterol compared with albuterol in patients with moderate-to-severe asthma: a randomized controlled trial.

2016-04-309 citations

Bronchodilator efficacy of the fixed combination of ipratropium and albuterol compared to albuterol alone in moderate-to-severe persistent asthma.

2008-03-0515 citations